Novo Nordisk is leveraging artificial intelligence to significantly reduce drug launch timelines, aiming for a two-thirds reduction in the process, according to a company executive. This initiative is part of the company's strategy to enhance its position in the growing obesity drug market.
John Dawber, managing director for global business services, indicated that traditional timelines for drug launches, which could take up to a year and a half from the last patient visit to the first regulatory filing, could now be shortened by several months through the implementation of AI. The company is integrating AI into various aspects of the drug launch process, including the preparation of regulatory documents, safety data analysis, and commercial analytics for both existing and trial drugs.
This move is reflective of a broader trend within the pharmaceutical industry, where companies are increasingly adopting AI to accelerate research, optimize workflows, and reduce costs. Projections suggest that machine learning could potentially halve early-stage development timelines in the next few years, but Novo Nordisk aims for even more aggressive improvements.
With its Bengaluru center taking a pivotal role, the site is responsible for a significant amount of preparatory work for global drug launches, including the recent introduction of an oral obesity medication in the U.S. Dawber noted that nearly every medicine launched globally has involved contributions from the Bengaluru team. Despite this expansion, the company plans to approach hiring conservatively, focusing on quality over quantity as it scales its AI-driven initiatives.